GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Cash Flow from Others

AdAlta (ASX:1AD) Cash Flow from Others : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is AdAlta Cash Flow from Others?

AdAlta's cash flow from others for the six months ended in Dec. 2023 was A$0.00 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.


AdAlta Cash Flow from Others Historical Data

The historical data trend for AdAlta's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Cash Flow from Others Chart

AdAlta Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cash Flow from Others
Get a 7-Day Free Trial - - - - -

AdAlta Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AdAlta Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

AdAlta Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of AdAlta's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


AdAlta Business Description

Traded in Other Exchanges
N/A
Address
2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083
AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

AdAlta Headlines

No Headlines